STRATA Skin Sciences (SSKN) Cash & Equivalents (2016 - 2025)
STRATA Skin Sciences (SSKN) has disclosed Cash & Equivalents for 14 consecutive years, with $7.9 million as the latest value for Q4 2025.
- Quarterly Cash & Equivalents rose 8.97% to $7.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.9 million through Dec 2025, up 8.97% year-over-year, with the annual reading at $7.9 million for FY2025, 8.97% up from the prior year.
- Cash & Equivalents hit $7.9 million in Q4 2025 for STRATA Skin Sciences, up from $7.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $13.0 million in Q3 2021 to a low of $2.8 million in Q1 2023.
- Historically, Cash & Equivalents has averaged $7.9 million across 5 years, with a median of $7.2 million in 2023.
- Biggest five-year swings in Cash & Equivalents: plummeted 74.14% in 2023 and later surged 85.38% in 2024.
- Year by year, Cash & Equivalents stood at $12.6 million in 2021, then crashed by 56.83% to $5.4 million in 2022, then rose by 24.84% to $6.8 million in 2023, then rose by 7.03% to $7.3 million in 2024, then increased by 8.97% to $7.9 million in 2025.
- Business Quant data shows Cash & Equivalents for SSKN at $7.9 million in Q4 2025, $7.1 million in Q3 2025, and $6.0 million in Q2 2025.